A Randomized Active-Controlled Study of AMG 162 in Breast Cancer Subjects With Bone Metastasis Who Have Not Previously Been Treated With Bisphosphonate Therapy.

Trial Profile

A Randomized Active-Controlled Study of AMG 162 in Breast Cancer Subjects With Bone Metastasis Who Have Not Previously Been Treated With Bisphosphonate Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Oct 2016

At a glance

  • Drugs Denosumab (Primary) ; Bisphosphonates
  • Indications Breast cancer; Cancer metastases
  • Focus Pharmacodynamics
  • Sponsors Amgen
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Jun 2009 Actual end date (Oct 2006) added as reported by ClinicalTrials.gov.
    • 01 Jun 2008 Results presented at the Annual Meeting of the American Society of Clinical Oncology 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top